In the following video, Motley Fool health-care analyst David Williamson discusses Optimer's (NASDAQ: OPTR) 10% jump on word that the company will look into "strategic alternatives" in the midst of its current difficult times. David speculates that this means the company may be looking to sell, and he discusses who some potential buyers might be.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Optimer looks at some "strategic" moves.
David Williamson owns shares of Pfizer. The Motley Fool recommends Cubist Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Pfizer
PFE
$23.98
(0.40%)
$0.10
Cubist Pharmaceuticals LLC
CBST.DL
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Should You Forget Medical Properties Trust and Buy These Unstoppable Dividend Stocks Instead?
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Is Oscar Health Stock Still a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.